JP2019508181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508181A5 JP2019508181A5 JP2018548884A JP2018548884A JP2019508181A5 JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5 JP 2018548884 A JP2018548884 A JP 2018548884A JP 2018548884 A JP2018548884 A JP 2018548884A JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- self
- cerebrospinal fluid
- leakage
- assembling peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 206010008164 Cerebrospinal fluid leakage Diseases 0.000 claims description 42
- 239000000017 hydrogel Substances 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 11
- 230000004962 physiological condition Effects 0.000 claims description 8
- 241001269524 Dura Species 0.000 claims description 6
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 claims description 4
- 239000012867 bioactive agent Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 19
- 208000004711 cerebrospinal fluid leak Diseases 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310122P | 2016-03-18 | 2016-03-18 | |
| US62/310,122 | 2016-03-18 | ||
| PCT/IB2017/000387 WO2017158435A1 (en) | 2016-03-18 | 2017-03-17 | Cerebrospinal fluid leakage occlusion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508181A JP2019508181A (ja) | 2019-03-28 |
| JP2019508181A5 true JP2019508181A5 (enExample) | 2020-04-23 |
Family
ID=58645333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548884A Pending JP2019508181A (ja) | 2016-03-18 | 2017-03-17 | 脳脊髄液の漏出の閉鎖 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210023257A1 (enExample) |
| EP (1) | EP3429645A1 (enExample) |
| JP (1) | JP2019508181A (enExample) |
| CN (1) | CN109195640A (enExample) |
| AU (1) | AU2017232550A1 (enExample) |
| BR (1) | BR112018068939A2 (enExample) |
| CL (1) | CL2018002643A1 (enExample) |
| MX (1) | MX2018011201A (enExample) |
| WO (1) | WO2017158435A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190022455A (ko) | 2016-03-18 | 2019-03-06 | 가부시끼가이샤 쓰리디 매트릭스 | 생물학적 조직 유착을 방지하는 방법 |
| EP4125995A4 (en) | 2020-03-31 | 2024-04-10 | 3-D Matrix, Ltd. | STERILIZATION OF SELF-ASSEMBLY PEPTIDES BY IRRADIATION |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9162005B2 (en) * | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
| AU2006241123B2 (en) * | 2005-04-25 | 2013-10-03 | Massachusetts Institute Of Technology | Compositions and methods for promoting hemostasis and other physiological activities |
| US7854923B2 (en) * | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
| HUE037994T2 (hu) * | 2006-04-25 | 2018-09-28 | Massachusetts Inst Technology | Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására |
| BRPI0920030B1 (pt) * | 2008-10-06 | 2019-03-26 | 3-D Matrix, Ltd. | Agente de oclusão do tecido, agentes hemostáticos, preventivos e de oclusão ou escleroterapia relacionados, e infusão do tecido mucosal |
| CN103800941B (zh) * | 2012-11-09 | 2015-04-22 | 北京银河巴马生物技术股份有限公司 | 一种i型胶原材料、脑膜或脊膜生物膜片及其制备方法和应用 |
| US20160287744A1 (en) * | 2012-11-14 | 2016-10-06 | 3-D Matrix Ltd. | Vascular embolic system |
| EP2968654A1 (en) * | 2013-03-14 | 2016-01-20 | 3-D Matrix, Ltd | Treatment for bile leakage |
-
2017
- 2017-03-17 US US16/085,803 patent/US20210023257A1/en not_active Abandoned
- 2017-03-17 CN CN201780030464.9A patent/CN109195640A/zh active Pending
- 2017-03-17 BR BR112018068939A patent/BR112018068939A2/pt not_active Application Discontinuation
- 2017-03-17 AU AU2017232550A patent/AU2017232550A1/en not_active Abandoned
- 2017-03-17 EP EP17720569.7A patent/EP3429645A1/en not_active Ceased
- 2017-03-17 WO PCT/IB2017/000387 patent/WO2017158435A1/en not_active Ceased
- 2017-03-17 JP JP2018548884A patent/JP2019508181A/ja active Pending
- 2017-03-17 MX MX2018011201A patent/MX2018011201A/es unknown
-
2018
- 2018-09-14 CL CL2018002643A patent/CL2018002643A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vigani et al. | Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes | |
| JP2019508175A5 (enExample) | ||
| CN104884065B (zh) | 治疗癌症的方法 | |
| BRPI0512397A (pt) | composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual | |
| US20230312700A1 (en) | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor | |
| JP2021520373A (ja) | Ｃｇｒｐを阻害する際に使用するための神経毒素 | |
| JP2014221830A5 (enExample) | ||
| US11419954B2 (en) | Targeted protein contrast agents, methods of making, and uses thereof | |
| JP2020509048A5 (enExample) | ||
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| JP2018512454A5 (enExample) | ||
| AU2017339970A1 (en) | Compounds and methods for activating Tie2 signaling | |
| BR112019020451A2 (pt) | composições e métodos para se direcionar e matar células-tronco positivas de câncer ?lfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento | |
| JP2019508181A5 (enExample) | ||
| JP2018500546A5 (enExample) | ||
| Shi et al. | Advances in nanotherapy for targeting senescent cells | |
| Sun et al. | Emerging nanotherapeutic strategies targeting gut-X axis against diseases | |
| Yadav et al. | Nano-enhanced peptides: bridging cutting-edge tech and biology to outsmart resilient microbes | |
| JP2021502337A5 (enExample) | ||
| EP4548924A3 (en) | Enhanced delivery of drugs and other compounds to the brain and other tissues | |
| JP2018527345A (ja) | ポリマーおよびその使用方法 | |
| Shunmugaperumal et al. | Multifunctional nanosized emulsions for theragnosis of life threatening diseases | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| Maduka et al. | Engineering nanoparticles that target fibroblast activation protein in cardiac fibrosis | |
| CN108273038B (zh) | 防治肠型放射病的药物组合物 |